Dutch Government gives 14 million Euros to DNDi to fight neglected tropical diseases

[Geneva, Switzerland – December 3, 2010]
The Ministry of Foreign Affairs of the Netherlands has granted 14 million Euros to the Drugs for Neglected Diseases initiative (DNDi) to fight neglected tropical diseases. The grant will be disbursed over four years (2011-2014) and will provide critical funding for DNDi on the core disease programmes for human African trypanosomiasis, Chagas disease, and leishmaniasis. This is the second time that the Dutch government has awarded funding to DNDi.

ASTMH 2010

[November 3-7, 2010]
Atlanta, USA
The Drugs for Neglected Diseases initiative (DNDi) will participate in several activities at ASTMH 2010, including a joint symposium with Central Drug Research Institute (CDRI) on Visheral Leishmaniasis (VL) in the Indian Continent, a second symposium on VL in East Africa, a satellite symposium on Challenges and Successes of the FACT Project through Innovative Partnerships for the development of Artesunate Combination Therapies for Malaria, as well as several oral presentations.

Geographical variation in the response of visceral leishmaniasis to Paromomycin in East Africa: A multicentre, open-label, randomized trial

by Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Muellerm, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, for the Leishmaniasis East Africa Platform (LEAP) group.

PLoS Negl Trop Dis, October 2010

New Potential TB Drugs to be Investigated Against Multiple Neglected Diseases

[New York, United States and Geneva, Switzerland – July 7, 2010]
A Unique Collaboration: TB Alliance and DNDi Enter Cross-Disease License Agreement to Speed Development of Novel Therapies
The Global Alliance for TB Drug Development (TB Alliance) and Drugs for Neglected Diseases initiative (DNDi) announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world’s poor. This agreement highlights the efficiency and synergy of product development partnerships (PDPs), and how investment in PDPs is producing a robust and diverse pipeline of tools to treat a wide variety of neglected diseases.

More Sustainable Resources Needed

[February 2010]
Despite the establishment of Product Development Partnerships like DNDi and new commitments from public and private donors, funding for scientific and medical innovation for diseases that disproportionately affect the developing world remains inadequate. DNDi and the George Institute launched in February 2010 a new report on the challenges of registering new drugs for neglected diseases in the African context.

Pfizer and DNDi Advancing International Research Efforts in The Fight Against Neglected Tropical Diseases

[New York, USA, Geneva, Switzerland – November 18, 2009]
Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.

Nederlandse overheid kent 14 miljoen euro toe aan DNDi voor de bestrijding van veronachtzaamde tropische ziekten

[Genève, Zwitserland, 3 december, 2010]
Het Nederlandse Ministerie van Buitenlandse Zaken heeft een bedrag van 14 miljoen Euro toegekend aan het Drugs for Neglected Diseases initiative (DNDi) voor de bestrijding van veronachtzaamde tropische ziekten. De subsidie wordt verdeeld over een periode van vier jaar (2011-2014) en vormt een cruciale bijdrage aan de fondsen voor de ‘core disease’-programma’s van DNDi voor Afrikaanse slaapziekte, deziekte van Chagas en Leishmaniase. Dit is de tweede keer dat de Nederlandse overheid een subsidie toekent aan DNDi.

ECOSOC – United Nations Economic and Social Council Innovation Fair

[July 6-9, 2009]
Geneva, Switzerland
DNDi participated at ECOSOC’s Innovation Fair at the High-Level Segment meeting, which took place in Geneva. This meeting and all the “satellite” activities presented good opportunities to discuss research & development issues, especially in the neglected diseases sector. DNDi had a booth at ECOSOC’s Innovation Fair and made a presentation about the Leishmaniasis East Africa Platform (LEAP), which is active in capacity building (infrastructure and training) and in conducting clinical trials in Kenya, Sudan, Ethiopia and in Uganda.

Drug Discovery Unit, University of Dundee, and DNDi Collaborate to Identify Drug Candidates to Treat Visceral Leishmaniasis

[ Dundee, UK, and Geneva, Switzerland June 22, 2009 ]
On the eve of an international meeting bringing together 200 African researchers to discuss progress on research for neglected tropical diseases (NTD), the Drug Discovery Unit University of Dundee, and Drugs for Neglected Diseases initiative (DNDi) announced today that they have initiated a collaboration on the discovery and development of affordable and effective therapies for visceral leishmaniasis (kala azar).

TB Alliance and DNDi Announce Collaborations with Anacor to Apply Boron Technology to Identify New Medicines for Neglected Diseases

[ Palo Alto, Calif., New York, NY and Geneva, Switzerland May 27, 2009 ]
Anacor Pharmaceuticals today announced that it has entered into a license and research agreement with not-for-profit Global Alliance for TB Drug Development (TB Alliance) to explore a novel anti-bacterial drug target for use in tuberculosis (TB) therapy.  Under the agreement, Anacor will provide the TB Alliance with a non-exclusive, royalty-free worldwide license for TB.

Un espoir de traitements pour les maladies infectieuses très négligées

[ Paris, Genève – 11 juin 2008 ]
L’Institut de Recherche pour le Développement (IRD) et la fondation Drugs for Neglected Diseases initiative (DNDi) annoncent aujourd’hui la mise en œuvre de projets de coopération scientifique pour le développement de médicaments contre la maladie de Chagas, la leishmaniose viscérale et  la maladie du Sommeil.

GlaxoSmithKline y Drugs for Neglected Diseases initiative (Iniciativa de Medicamentos para las Enfermedades Olvidadas) colaborarán en proyectos de investigación para cubrir necesidades de salud pública en los países en desarrollo

[ Madrid – 6 de marzo de 2008 ]
GlaxoSmithKline (GSK) y la organización sin ánimo de lucro Drugs for Neglected Diseases initiative (DNDi) han anunciado hoy un proyecto de colaboración en investigación sobre enfermedades tropicales olvidadas que afectan significativamente en países en desarrollo.